Loading
Nirali Shah developed CD22 CAR-T for children whose leukaemia escaped CD19 therapy.
Nirali N. Shah is Head of the Hematologic Malignancies Section in the Pediatric Oncology Branch at the National Cancer Institute. She is a paediatric leukaemia specialist known for developing CD22-directed CAR-T for children whose acute lymphoblastic leukaemia escaped CD19 therapy, addressing CD19-negative relapse after tisagenlecleucel and blinatumomab. Her selected paper reports that CD22-targeted CAR T cells induce remission in B-cell acute lymphoblastic leukaemia that is naive or resistant to CD19-targeted CAR immunotherapy. She leads paediatric CAR-T trials at NCI.
| Title | Journal | Year |
|---|---|---|
| CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy | Nature Medicine | 2018 |
Shares CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia.
Shares CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia.
Shares CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia.
Shares CD19, Acute lymphoblastic leukaemia.
Shares CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia.
Shares NCI Center for Cancer Research (intramural programme), National Cancer Institute (NIH).
Shares NCI Center for Cancer Research (intramural programme), National Cancer Institute (NIH).
Shares NCI Center for Cancer Research (intramural programme), National Cancer Institute (NIH).